Treamid Therapeutics GmbH

Treamid Therapeutics is a Berlin-based pharma SME that was funded in 2017. It owns a portfolio of patent-protected, new chemical entities, addressing new targets in inflammatory and fibrotic respiratory diseases. Our office and own in vitro laboratory are based at the Biotech Campus Berlin. 

Our vision is to develop safe, effective, and transformative drugs with a focus on more than half a billion patients suffering from chronic respiratory diseases. We want to achieve this by developing breakthrough treatments beyond merely alleviating or managing symptoms but offering the potential for disease modification, improved survival, and long-term remission. 

Our mission is to develop our portfolio of preclinical new chemical entities towards clinical proof of safety and efficacy and subsequently through development partnerships to market approval.

Our development programs focus on IPF, chronic obstructive pulmonary disease and other forms of fibrotic and inflammatory pulmonary diseases. Patients with these diseases experience breathlessness reduced physical functioning, and severely impaired quality of life. Our lead development candidate
XC7 for IPF is our main focus and will pave the way for our broader, early-stage development portfolio for respiratory diseases and other fibrotic areas like liver fibrosis.

Our approach to drug development is rooted in state-of-the-art peer-reviewed scientific research in inflammatory and fibrotic diseases and a solid understanding of the underlying disease mechanisms and disease targets in these indications. We comprise a team with many years of experience in start-up and big pharma drug development, application of state-of-the-art R&D technologies such as in silico modelling for target identification and validation, sequencing techniques and 3D cell culture models. 

We collaborate with leading European researchers, opinion leaders, and clinical investigators in IPF and COPD, and patient advocacy groups such as the European Patient Society for IPF, to ensure that our research strategy and study designs are guided by the latest scientific advancements, real-world insights, needs and perspectives of the relevant stakeholders in our field.